May 23, 2022
Next month, federal regulators will begin the review of Moderna’s and Pfizer-BioNTech’s COVID-19 vaccines for use in young children.
Today, Pfizer-BioNTech announced it was submitting new clinical trial data indicating its vaccine was more than 80 percent effective for children between 6 months and 5 years old during the Omicron wave. The announcement comes after Moderna said it was finalizing its submissions to the FDA last month.
“Our COVID-19 vaccine has been studied in thousands of children and adolescents, and we are pleased that our formulation for the youngest children, which we carefully selected to be one-tenth of the dose strength for adults, was well tolerated and produced a strong immune response,” Albert Bourla, chairman and CEO of Pfizer said in a statement.
Here’s what you need to know:
HAP will continue to monitor the latest COVID-19 public health developments and provide updates to members.
With COVID-19 subvariants leading to a new increase in cases, HAP encourages everyone who is eligible to make an appointment to receive the COVID-19 vaccine or a booster dose. Don’t hesitate to contact your health care provider for questions or for more information about the available vaccines.
More information about COVID-19 vaccines is available online.
Click on topic below for category-specific news articles.
Support a healthier Pennsylvania.